We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

132 hedge funds and large institutions have $575M invested in Cytokinetics in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 39 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more call options, than puts

Call options by funds: $9.37M | Put options by funds: $6.62M

36% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 39

24% more capital invested

Capital invested by funds: $465M → $575M (+$111M)

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

3% less funds holding

Funds holding: 136 → 132 (-4)

4.93% less ownership

Funds ownership: 78.84% → 73.92% (-4.9%)

Holders
132
Holders Change
-4
Holders Change %
-2.94%
% of All Funds
3.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
53
Reduced
39
Closed
20
Calls
$9.37M
Puts
$6.62M
Net Calls
+$2.75M
Net Calls Change
-$134K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$15.7M
2
PA
Pinnacle Associates
New York
+$13.8M
3
BlackRock
BlackRock
New York
+$8.16M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.81M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.69M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$10.2M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$5.02M
3
BIM
Bogle Investment Management
Massachusetts
-$4.96M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$4.3M
5
LCM
Laurion Capital Management
New York
-$3.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
AWM
126
Avior Wealth Management
Nebraska
$3K -$410 -30 -17%
HR
127
Howe & Rusling
New York
$2K – – –
GEA
128
Glen Eagle Advisors
New Jersey
$1.81K +$1.71K +125 New
TWA
129
TCI Wealth Advisors
Arizona
$1K – – –
US Bancorp
130
US Bancorp
Minnesota
$1K – – –
BIM
131
Bogle Investment Management
Massachusetts
– -$4.96M -409,679 Closed
LCM
132
Laurion Capital Management
New York
– -$3.93M -324,693 Closed
OAM
133
Oxford Asset Management
United Kingdom
– -$1.62M -134,002 Closed
SIM
134
Spark Investment Management
New York
– -$755K -62,400 Closed
SCM
135
Sterling Capital Management
North Carolina
– -$634K -52,388 Closed
MCM
136
Moore Capital Management
New York
– -$605K -50,000 Closed
Millennium Management
137
Millennium Management
New York
– -$504K -41,639 Closed
SCM
138
Stevens Capital Management
Pennsylvania
– -$495K -40,924 Closed
FRM
139
Fox Run Management
Connecticut
– -$436K -36,000 Closed
Jacobs Levy Equity Management
140
Jacobs Levy Equity Management
New Jersey
– -$393K -32,464 Closed
HCM
141
Highbridge Capital Management
New York
– -$314K -25,910 Closed
AIM
142
Alambic Investment Management
California
– -$205K -16,949 Closed
GAM
143
Gotham Asset Management
New York
– -$204K -16,860 Closed
DTL
144
Dynamic Technology Lab
Singapore
– -$177K -14,602 Closed
FAM
145
Fortaleza Asset Management
Illinois
– -$125K -10,345 Closed
QT
146
Quantbot Technologies
New York
– -$56K -4,708 Closed
VWA
147
V Wealth Advisors
Kansas
– -$6K -500 Closed
NIT
148
NumerixS Investment Technologies
British Columbia, Canada
– -$1K -100 Closed
Creative Planning
149
Creative Planning
Kansas
– -$1K -83 Closed
AIM
150
Acrospire Investment Management
Illinois
– -$1K -81 Closed
3 4 5
6
7

CYTK Hedge Fund Activity: Q3 2017 in Review

132 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2017, worth a combined $575M — up 24% from $465M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CYTK and 19 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 53 added.

The largest buyer was Citadel Advisors, adding an estimated $15.7M. The largest seller was BVF Inc, cutting an estimated $10.2M.

  • 132 institutional investors held Cytokinetics (CYTK) as of Q3 2017, down from 136 in Q2 2017.
  • Funds reported $575M of Cytokinetics stock for Q3 2017, up 24% quarter-over-quarter.
  • 19 funds opened new Cytokinetics positions in Q3 2017 and 20 closed out, a net change of -1 holder.
  • The largest Cytokinetics buyer in Q3 2017 was Citadel Advisors, an estimated $15.7M added.
  • The largest Cytokinetics seller in Q3 2017 was BVF Inc, an estimated $10.2M sold.

Based on aggregated 13F filings for Q3 2017.